Cash Flow Nurix Therapeutics, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Nov'25
Nov'24
Nov'23
Nov'22
Nov'21
Nov'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-263.00
-193.00
-143.00
-180.00
-117.00
-63.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-31.00
-18.00
20.00
-19.00
9.00
36.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-249.00
-172.00
-81.00
-159.00
-84.00
0.00
Cash Flow from Investing Activities
147.00
-257.00
68.00
27.00
-108.00
-254.00
Cash Flow from Financing Activities
238.00
485.00
3.00
117.00
153.00
339.00
Net Cash Inflow / Outflow
137.00
55.00
-9.00
-15.00
-38.00
84.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Nurix Therapeutics, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-263.697
-219.879
-44.00
-19.93%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-31.596
14.084
-45.00
-324.34%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-249.465
-175.75
-74.00
-41.94%
Cash Flow from Investing Activities
147.853
179.989
-32.00
-17.85%
Cash Flow from Financing Activities
238.642
1.088
237.00
21834.01%
Net Cash Inflow / Outflow
137.03
5.327
132.00
2472.37%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Nov'25
YoY Growth in year ended Nov 2025 is -44.55% vs -112.11% in Nov 2024
Nov'25
Nov'24
Change(%)
Cash Flow from Operating Activities
-249.47
-172.58
-44.55%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
